Long-Term Exclusive Zinc Monotherapy in Symptomatic Wilson Disease: Experience in 17 Patients

被引:64
作者
Linn, Francisca H. H. [2 ,3 ,4 ]
Houwen, Roderick H. J. [5 ]
van Hattum, Jan [6 ]
van der Kleij, Stefan [5 ]
van Erpecum, Karel J. [1 ]
机构
[1] Univ Med Ctr, Dept Gastroenterol, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr, Dept Neurol, NL-3508 GA Utrecht, Netherlands
[3] Rudolf Magnus Inst Neurosci, NL-3508 TA Utrecht, Netherlands
[4] Cent Mil Hosp, Utrecht, Netherlands
[5] Univ Med Ctr, Dept Pediat, NL-3508 GA Utrecht, Netherlands
[6] Kliniek Berg Bosch, Bilthoven, Netherlands
关键词
FOLLOW-UP; THERAPY; DIAGNOSIS; SULFATE; PENICILLAMINE; MANAGEMENT;
D O I
10.1002/hep.23182
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Exclusive monotherapy with zinc in symptomatic Wilson disease is controversial. Seventeen symptomatic patients with Wilson disease were treated with zinc only. The mean age at diagnosis and start of treatment was 18 years (range 13-26) with approximately half presenting as adolescents. Presentation was exclusively hepatic, exclusively neurologic, and combined in seven, five, and five patients, respectively. The median follow-up was 14 years (range 2-30). At baseline, two of the 12 patients with hepatic disease exhibited decompensated cirrhosis, five exhibited compensated cirrhosis, and five had less severe disease. Both patients with decompensated cirrhosis improved to a compensated state after initiation of therapy. Two of the five patients with initial compensated cirrhosis progressed to decompensated state, and three remain stable. Three of the five patients with moderate or mild liver disease remain stable and two improved. Apart from decreasing bilirubin levels, no significant changes occurred in the liver biochemistry or function during long-term follow-up. Nine of 10 neurologic patients improved markedly and one deteriorated. Two patients with exclusively neurologic presentation developed liver disease during zinc treatment. Two patients with exclusively hepatic presentation developed mild neurologic symptoms. According to 24-hour urinary copper excretions (213 +/- 38 versus 91 +/- 23 mu g: P = 0.01) and serum non-ceruloplasmin-bound copper concentrations (11 +/- 2 versus 7 +/- 1 mu g/dL: P = 0.1) at the end of follow-up, the efficacy of decoppering was less in the exclusively hepatic than in the neurologic group. The prescribed zinc dose and 24-hour urinary zinc excretions tended to be less in the exclusively hepatic group. Conclusion: The outcome of exclusive zinc therapy is generally good in cases of neurologic disease. A less satisfactory outcome in hepatic disease may relate to less efficient decoppering. (HEPATOLOGY 2009;50:1442-1452.)
引用
收藏
页码:1442 / 1452
页数:11
相关论文
共 17 条
[1]  
ALEXIOU D, 1985, ARCH FR PEDIATR, V42, P447
[2]   ORAL ZINC THERAPY FOR WILSONS-DISEASE [J].
BREWER, GJ ;
HILL, GM ;
PRASAD, AS ;
COSSACK, ZT ;
RABBANI, P .
ANNALS OF INTERNAL MEDICINE, 1983, 99 (03) :314-320
[3]   Treatment of Wilson's disease with zinc: XV - Long-term follow-up studies [J].
Brewer, GJ ;
Dick, RD ;
Johnson, VD ;
Brunberg, JA ;
Kluin, KJ ;
Fink, JK .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (04) :264-278
[4]   WORSENING OF NEUROLOGIC SYNDROME IN PATIENTS WITH WILSONS-DISEASE WITH INITIAL PENICILLAMINE THERAPY [J].
BREWER, GJ ;
TERRY, CA ;
AISEN, AM ;
HILL, GM .
ARCHIVES OF NEUROLOGY, 1987, 44 (05) :490-493
[5]   Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate [J].
Czlonkowska, A ;
Gajda, J ;
Rodo, M .
JOURNAL OF NEUROLOGY, 1996, 243 (03) :269-273
[6]   MANAGEMENT OF WILSONS-DISEASE WITH ZINC-SULFATE - EXPERIENCE IN A SERIES OF 27 PATIENTS [J].
HOOGENRAAD, TU ;
VANHATTUM, J ;
VANDENHAMER, CJA .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1987, 77 (2-3) :137-146
[7]   Paradigm shift in treatment of Wilson's disease: Zinc therapy now treatment of choice [J].
Hoogenraad, TU .
BRAIN & DEVELOPMENT, 2006, 28 (03) :141-146
[8]   ORAL ZINC-SULFATE AS LONG-TERM TREATMENT IN WILSONS DISEASE (HEPATOLENTICULAR DEGENERATION) [J].
HOOGENRAAD, TU ;
KOEVOET, R ;
DERUYTERKORVER, EGWM .
EUROPEAN NEUROLOGY, 1979, 18 (03) :205-211
[9]   Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: A single-hospital, 10-year follow-up study [J].
Marcellini, M ;
Di Ciommo, V ;
Callea, F ;
Devito, R ;
Comparcola, D ;
Sartorelli, MR ;
Carelli, F ;
Nobili, V .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2005, 145 (03) :139-143
[10]   Diagnosis and management of Wilson's disease -: Results of a single center experience [J].
Medici, Valentina ;
Trevisan, Carlo Pietro ;
D'Inca, Renata ;
Barollo, Michela ;
Zancan, Lucia ;
Fagiuoli, Stefano ;
Martines, Diego ;
Irato, Paola ;
Sturniolo, Giacomo Carlo .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2006, 40 (10) :936-941